Search This Blog

Saturday, January 13, 2018

What to follow in 2018



This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

What to follow in 2018

By Charles-Edouard!

Our friend Myriam does not cool down:


You're right, my dear! Happy New Year and good health to you!

Quatuor


Recruitment is over! Some see it as a sign of strong demand ... Well ... It had been announced 18 months ago and it is late, so recruiters have had ample time to pre-recruit. It's like Corsican ballots: they are full before the elections!

Morlat is a recommendation: not just a case-by-case authorization


We will argue that Morlat recommendation (French Guidelines) is indeed a recommendation; Also note ( as anticipated) the back-pedaling of EACS recommandation.

Genvoya®, Juluca®, Isentress HD®, Zentiva®, AF2B


The regulatory battle is launched! Big Euro-gov will not protect you from over-medication! (read)

Achilles Heel, DOMONO, Absolutegravir, Lanzafame


This subject remains very active. DOMONO has demonstrated the possibility of near-remission (sic): DTG behaves like an Absolutegravir, provided that one preserves one's therapeutic options.

Dual therapies


The variety merchants will give it their best. See the review of the Sword-1 & 2 trials. Question: it works at 100%: did not we overload the mule?

Another recent topic: Mono-DTG would be more favorable than Bi-DTG (and therefore TRIUMEQ®) in the remissionist view of ours ... To be continued...

Leibowitch and the new ICCARRE website


It's new and lacks substance ... It will come ... so, watch for it... Obviously, we will not duplicate, so for ourselves, we reroute our subject to 1/7, Hypodolu, and functional remission. We will discuss the news (there are some ...) in non-infectiousness ...

Transparency, Social Security, Freedom


Well, you have seen the government morgue during the compulsory vaccination and change for the new Levothyrox: citizens react and complain. As for this mainstream newspaper prefers to call patients morons rather than blame itself!

dolutegravir prise hebdomadaire pharmacocinétique estomac

Beyond once-weekly, once-monthly treatment


Buzz in Le Figaro an oral medicine that stays 7 days in the stomach and will allow to go further: we will see how this will allow the monthly 'oral' treatment. The official publication is here.

Reservoirs: things are moving!


The sacrosanct anti-remission dogma is disintegrating: we can twick the reservoirs ...

Half-a-pill strategies


Big success of my post Half-a-pill. Easy and useful strategy: worth working on!

Can we alleviate all treatments ?


We will discuss this subject which is equivalent to "is every treatment overdosed?". Since the inactive HIV dynamics (under control) is different from the active HIV dynamics, for which the dose is defined, obviously everything becomes overdosed, as it goes under control.

remissions


Yes, I promise, we get to this serious topic, I'll develop this year!

Practical Guide 1/7


In the absence of an 'Official' Therapeutic Guide, the most stupid rumors circulated about ICCARRE: our Practical Guide 4/7 put an end to all these imbecilities, skilfully maintained. Now it is the turn of the medics: circulates in Maghreb, a 'subsidized' training (financed by whom? Look for yourself) which repeats again the stupidities of yesteryear.


The refusal to publish a Practical Guide leaves the field tocrooks. If people have time to lose in logorrhea, they can devote a little to what will be useful and practical, right? It takes a lot of time, and this year we start the 1/7 Practical Guide!

The book


Our charts (here and here) have been successful! So, Charles-Edouard! prepares the book. Oh yes!...

Have a good Week, good fuck and do not abuse of meds/drugs

Feel free to comment, to like to share and to use

Have a good Week, good fuck and do not abuse of meds/drugs



This was originally published here, in French. We provide this translation for your convenience, practical aspects may differ where you live.

No comments: